Ring Therapeutics Presents New Data on Anellogy™ Platform at the 27th Annual American Society of Gene & Cell Therapy Conference
2024年5月7日 - 7:00PM
Ring Therapeutics, a life sciences company founded by Flagship
Pioneering to revolutionize genetic medicines with its commensal
virome platform, today announced new preclinical data demonstrating
successful transduction and redosability of its Anellovector within
non-human primates, as well as expanded payload capacity for the
vector beyond the natural genome size of anelloviruses (ANV). The
data, which will be presented as one oral presentation and two
posters at the 27th Annual America Society of Gene & Cell
Therapy (ASGCT) conference, showcases the viability of
Anellovectors as the next generation of viral vectors.
"I am thrilled that our Ring team has achieved this
significant milestone in non-human primates showcasing
transduction, redosability, and expanded payload capacity of
Anellovectors,” said Tuyen Ong, MD, MBA, Chief Executive Officer of
Ring Therapeutics and CEO-Partner at Flagship Pioneering. “Only a
few short years ago, we set out to create a safe and effective
viral vector from a human commensal virus, and the NHP data
provides critical insights into how Anellovectors may work in
humans. Additionally, the expanded payload capacity of
Anellovectors widens the therapeutic potential of this novel vector
class allowing even more patients to be potentially treated. These
data demonstrate our significant progress in advancing
Anellovectors towards the clinic, positioning Ring another step
closer to delivering life-changing therapies for patients.”
Presentation details and key highlights
below:
Expanded Payload Capacity
Title: Anellovectors: Expanding
the Payload Capacity of Anellovirus-Based Vectors Beyond the
Wild-Type Genome CapacityAbstract number:
450Presenter: Cato PrincePresentation
location, date, and time: Exhibit Hall, Wed, May 8, 12:00
PM ET
- Using vector genomes of increasing size, we have demonstrated
that Anellovectors are capable of packaging vector genomes up to
5.0kb, representing up to 65% beyond the wild-type genome
capacity.
- The overall potential for Anellovector cargo capacity appears
to exceed the ~4.7 kb cargo capacity of Adeno-associated viruses
(AAV).
- Unlike AAV, which appears to exhibit a strict packaging limit,
Anellovectors allow for the packaging of genomes larger than the
wild-type genome.
- A combination of qPCR and next-generation sequencing was used
to verify that the encapsidated expanded cargo DNA is intact,
circular, and single-stranded.
- Expanding the Anellovector's payload capacity builds upon its
intrinsic characteristics of immune favorability and tropism in
efforts to reach the broadest possible patient population in need
of gene therapies.
Transduction and Redosability in
NHPs
Title: Anellovector Derived from
Human Retinal Pigment Epithelium Delivers and Expresses a
Therapeutically Relevant DNA Payload in the Retina of Nonhuman
PrimatesAbstract number:
444Presenter: Parmi ThakkerPresentation
location, date, and time: Exhibit Hall, Wed, May 8, 12:00
PM ET
- Anellovectors, when administered intravitreally in NHPs,
demonstrated transgene infectivity and expression in ocular
tissues.
- Additionally, we observed significant increase in transgene
infectivity and expression in the neuroretina of the eye that
received a repeat dose compared to the eye treated only once,
showcasing the Anellovector’s potential for redosing as well with
no signs of ocular toxicity.
- These data are the first demonstration of therapeutic payload
delivery with an ANV vector and represent an initial investigation
into the potential use of this novel platform to treat eye diseases
such as wet AMD.
Anellovector Platform Overview
Title: Anellovectors, a Gene
Delivery Platform Based on Commensal Human Anelloviruses, Have the
Potential to Evade the Immune System and Deliver DNA Payloads to a
Broad Range of Tissues in a Redosable
MannerSpeaker: Chris Wright, MD, PhD – Chief
Medical Officer at Ring TherapeuticsSession Title and
Location: Emerging Viral Vectors – Ballroom 4, Baltimore
Convention CenterPresentation time: Thurs, May 9,
5:00 – 5:15 PM ET
About Ring Therapeutics
Ring Therapeutics is revolutionizing the genetic
medicines and nucleic acid space by harnessing the most abundant
and diverse member of the human commensal virome, anelloviruses.
The company developed the Anellogy™ platform which focuses on
anelloviruses to potentially treat a broad range of diseases.
Through harnessing the unique properties of these commensal
viruses, the Anellogy™ platform generates diverse vectors that
exhibit both tissue-specific tropism and the potential to be
re-dosed. Ring Therapeutics, founded by Flagship Pioneering in
2017, aims to develop and further expand its portfolio by
leveraging its platform to unlock the full potential of gene
therapy and nucleic acid medicines, enabling a variety of
mechanisms that successfully deliver therapeutic cargo to
unreachable organs and tissues. To learn more, visit
https://www.ringtx.com/ or follow us on X (Twitter) at
@Ring_tx.
Press ContactsRing Therapeutics
MediaBrittany Leigh, PhDLifeSci
Communicationsbleigh@lifescicomms.com813-767-7801